News and Press Releases
Press releases
Theralase® Investor Conference Call Reminder
Press ReleaseNov 17, 2025 7:00 AM EST Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario–(Newsfile Corp. – November 17, 2025) – Theralase® Technologies ...
Theralase® Releases 3Q2025 Financial Statements
Press ReleaseNov 10, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 10, 2025) – Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound ...
Theralase® Demonstrates Effectiveness of X-Ray-Activated Drug
Press ReleaseNov 3, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 3, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation...
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Press ReleaseSep 24, 2025 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – September 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiat...
Theralase® Extends Warrants
Press ReleaseAug 29, 2025 4:30 PM EDT Toronto, Ontario–(Newsfile Corp. – August 29, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation...
Theralase® Releases 2Q2025 Financial Statements
Press ReleaseToronto, Ontario–(Newsfile Corp. – August 26, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therap...
Theralase® Extends Warrants
Press ReleaseTheralase® Technologies Inc. plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028. The warrants, issued in 2023, remain exercisable at $0.35 per share under the same terms. The...
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® Technologies Inc. closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each. Funds will support its Phase II bladder cancer trial, Rutherrin® development, and corporate needs. Each unit includes a share and...
Theralase® Completes Annual General and Special Meeting
Press ReleaseTheralase® successfully completed its 2025 Annual General Meeting, sharing strategic plans for 2025–2026 focused on clinical advancements and commercialization. A recording of the presentation is available for shareholders....
Theralase® Annual General Meeting
Press ReleaseTheralase® Technologies Inc. reminds shareholders of its Annual General and Special Meeting (AGSM) on June 11, 2025, at 4:30 pm ET in Toronto. Following the meeting, a virtual corporate presentation and Q&A session will be held at 5:15...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
